|
2024 Journal Article Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology. doi: 10.1002/ajh.27459 |
|
2024 Conference Publication First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led studyChong, Geoffrey, Palmer, Jodie, Barraclough, Allison, Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza Anne (2024). First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.tps7092 |
|
2024 Conference Publication First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO studyChong, Geoffrey, Lee, Denise, Lee, Sze Ting, Grobler, Anneke, Khor, Richard, Campbell, Belinda A., Thachil, Thanuja, Manos, Kate, Martynchyk, Arina, Douglas, Genevieve, Keane, Colm, Palmer, Jodie and Hawkes, Eliza Anne (2024). First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7070 |
|
2024 Conference Publication A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysisTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Peter, Borchmann, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Torzan, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7056 |
|
2024 Conference Publication A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysisTimmerman, John, Lavie, David, Peter, Borchmann, Gregory, Gareth P., Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Johnson, Nathalie A. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7055 |
|
2024 Journal Article Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillanceWight, Joel, Blombery, Piers, Lickiss, Jennifer, Burgess, Melinda, Gould, Clare, Minson, Adrian, Swain, Fiona, Sabdia, Muhammed B., Gandhi, Maher K., Birchley, Andrew, Keane, Colm and Hawkes, Eliza A (2024). Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance. Haematologica. doi: 10.3324/haematol.2023.284600 |
|
2024 Journal Article Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyBarraclough, Allison, Agrawal, Shivam, Talaulikar, Dipti, Chong, Geoffrey, Yoo, Edward, Cheah, Chan Y., Franco, Nunzio, Nguyen, Bianca, Mutsando, Howard, Tahir, Fatima, Trotman, Judith, Huang, Jing, Keane, Colm, Lincoln, Mitchel, Cochrane, Tara, Johnston, Anna M., Dickinson, Michael, Opat, Stephen, McQuilten, Zoe K., Wood, Erica M., St George, Gayathri and Hawkes, Eliza A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica. doi: 10.3324/haematol.2023.284538 |
|
2024 Journal Article Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectShaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A. (2024). Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem, 5 (2), 325-332. doi: 10.1002/jha2.870 |
|
2024 Journal Article Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironmentAlim, Louisa F, Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2024). Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Current Opinion in Immunology, 86 102409, 102409. doi: 10.1016/j.coi.2023.102409 |
|
2024 Journal Article Epstein–Barr virus‐associated lymphomas decodedBednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv and Gandhi, Maher K. (2024). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204 (2), 415-433. doi: 10.1111/bjh.19255 |
|
2023 Conference Publication Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 StudyJohnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182128 |
|
2023 Conference Publication Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 StudyTimmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182019 |
|
2023 Conference Publication Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated StudyChong, Geoff, Palmer, Jodie B., Barraclough, Allison A., Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza A. (2023). Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173110 |
|
2023 Journal Article Prognostic markers within the tumour microenvironment in classical Hodgkin lymphomaMartynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A. and Keane, Colm (2023). Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma. Cancers, 15 (21) 5217, 1-21. doi: 10.3390/cancers15215217 |
|
2023 Journal Article Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaCass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007 |
|
2023 Conference Publication Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin LymphomaJohnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin Lymphoma. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971156.02746.02 |
|
2023 Conference Publication Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 TreatmentTimmerman, John, Lavie, David, Johnson, Nathalie, Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Luigi Zinzani, Pier, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 Treatment. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971168.59900.67 |
|
2023 Conference Publication T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor StudyKoldej, Rachel, Barraclough, Allison, Ting Lee, Sze, Morgan, Huw, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Ting, Stephen, Churilov, Leonid, Ritchie, David and Hawkes, Eliza A. (2023). T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor Study. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971812.42966.2d |
|
2023 Conference Publication Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) StudyShaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoff, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A (2023). Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) Study. EHA2023, Online, 8 - 15 June 2023. Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/01.hs9.0000971668.24670.ab |
|
2023 Journal Article C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsBonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993 |
